Characterization of susceptibility variants of poliovirus grown in the presence of favipiravir

Journal of Microbiology, Immunology and Infection

Volumn 51, Issue 5, 2018, Pages 581-586

  Daikoku, Tohru ^a,b   Mizuguchi, Mineyuki ^a   Obita, Takayuki ^a   Yokoyama, Takeshi ^a   Yoshida, Yoshihiro ^a   Takemoto, Masaya ^a,b   Shiraki, Kimiyasu ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b HOKURIKU UNIVERSITY   (Japan)

Author keywords

Favipiravir; Mutants; Poliovirus; Resistance; RNA dependent RNA polymerase; T 705

Indexed keywords

FAVIPIRAVIR; RIBAVIRIN; RNA POLYMERASE; AMIDE; ANTIVIRUS AGENT; PROTEIN BINDING; PYRAZINE DERIVATIVE; RNA DIRECTED RNA POLYMERASE; VIRAL PROTEIN;

AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ARTICLE; CYTOPATHOGENIC EFFECT; IC50; NONHUMAN; NUCLEOTIDE SEQUENCE; POLIOMYELITIS VIRUS; PROTEIN DOMAIN; SEQUENCE ANALYSIS; VERO CELL LINE; VIROGENESIS; VIRUS CULTURE; VIRUS ISOLATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; CHLOROCEBUS AETHIOPS; DRUG EFFECT; ENZYMOLOGY; GENETICS; METABOLISM; MOLECULAR MODEL; MUTATION; PHYSIOLOGY; VIRUS REPLICATION;

AMIDES; ANIMALS; ANTIVIRAL AGENTS; CERCOPITHECUS AETHIOPS; DRUG RESISTANCE, VIRAL; MODELS, MOLECULAR; MUTATION; POLIOVIRUS; PROTEIN BINDING; PYRAZINES; RNA REPLICASE; VERO CELLS; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 85023191793     PISSN: 16841182     EISSN: 19959133     Source Type: Journal    
DOI: 10.1016/j.jmii.2017.03.004     Document Type: Article

References (40)

1. Takahashi, K., Furuta, Y., Fukuda, Y., Kuno, M., Kamiyama, T., Kozaki, K., et al. In vitro and in vivo activities of T-705 and oseltamivir against influenza virus. Antivir Chem Chemother 14 (2003), 235–241.
2. Furuta, Y., Takahashi, K., Fukuda, Y., Kuno, M., Kamiyama, T., Kozaki, K., et al. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother 46 (2002), 977–981.
3. Furuta, Y., Takahashi, K., Kuno-Maekawa, M., Sangawa, H., Uehara, S., Kozaki, K., et al. Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother 49 (2005), 981–986.
4. Furuta, Y., Gowen, B.B., Takahashi, K., Shiraki, K., Smee, D.F., Barnard, D.L., Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res 100 (2013), 446–454.
5. Furuta, Y., Takahashi, K., Shiraki, K., Sakamoto, K., Smee, D.F., Barnard, D.L., et al. T-705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res 82 (2009), 95–102.
6. Oestereich, L., Ludtke, A., Wurr, S., Rieger, T., Munoz-Fontela, C., Gunther, S., Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Res 105 (2014), 17–21.
7. Oestereich, L., Rieger, T., Neumann, M., Bernreuther, C., Lehmann, M., Krasemann, S., et al. Evaluation of antiviral efficacy of ribavirin, arbidol, and T-705 (favipiravir) in a mouse model for Crimean-Congo hemorrhagic fever. PLoS Negl Trop Dis, 8, 2014, e2804.
8. Oestereich, L., Rieger, T., Ludtke, A., Ruibal, P., Wurr, S., Pallasch, E., et al. Efficacy of favipiravir alone and in combination with ribavirin in a lethal, immunocompetent Mouse Model of Lassa fever. J Infect Dis 213 (2016), 934–938.
9. Delang, L., Segura Guerrero, N., Tas, A., Querat, G., Pastorino, B., Froeyen, M., et al. Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral. J Antimicrob Chemother 69 (2014), 2770–2784.
10. Tani, H., Fukuma, A., Fukushi, S., Taniguchi, S., Yoshikawa, T., Iwata-Yoshikawa, N., et al. Efficacy of T-705 (favipiravir) in the treatment of infections with lethal severe fever with thrombocytopenia syndrome virus. mSphere, 2016, 1.
11. Yamada, K., Noguchi, K., Komeno, T., Furuta, Y., Nishizono, A., Efficacy of favipiravir (T-705) in Rabies postexposure prophylaxis. J Infect Dis 213 (2016), 1253–1261.
12. Safronetz, D., Falzarano, D., Scott, D.P., Furuta, Y., Feldmann, H., Gowen, B.B., Antiviral efficacy of favipiravir against two prominent etiological agents of hantavirus pulmonary syndrome. Antimicrob Agents Chemother 57 (2013), 4673–4680.
13. Arias, A., Thorne, L., Goodfellow, I., Favipiravir elicits antiviral mutagenesis during virus replication in vivo. eLife, 3, 2014, e03679.
14. Bai, C.Q., Mu, J.S., Kargbo, D., Song, Y.B., Niu, W.K., Nie, W.M., et al. Clinical and virological characteristics of Ebola virus disease patients treated with favipiravir (T-705), Sierra Leone, 2014. Clin Infect Dis 63:10 (2016 Nov 15), 1288–1294 Epub 2016 Aug 23.
15. Sissoko, D., Laouenan, C., Folkesson, E., M'Lebing, A.B., Beavogui, A.H., Baize, S., et al. Experimental treatment with favipiravir for Ebola virus disease (the JIKI trial): a historically controlled, single-arm proof-of-concept trial in Guinea. PLoS Med, 13, 2016, e1001967.
16. Sangawa, H., Komeno, T., Nishikawa, H., Yoshida, A., Takahashi, K., Nomura, N., et al. Mechanism of action of T-705 ribosyl triphosphate against influenza virus RNA polymerase. Antimicrob Agents Chemother 57 (2013), 5202–5208.
17. Jin, Z., Smith, L.K., Rajwanshi, V.K., Kim, B., Deval, J., The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) Ribofuranosyl 5′-triphosphate towards influenza A virus polymerase. PLoS One, 8, 2013, e68347.
18. Daikoku, T., Yoshida, Y., Okuda, T., Shiraki, K., Characterization of susceptibility variants of influenza virus grown in the presence of T-705. J Pharmacol Sci 126 (2014), 281–284.
19. Agol, V.I., Molecular mechanisms of poliovirus variation and evolution. Curr Top Microbiol Immunol 299 (2006), 211–259.
20. Kempf, B.J., Barton, D.J., Picornavirus RNA polyadenylation by 3D(pol), the viral RNA-dependent RNA polymerase. Virus Res 206 (2015), 3–11.
21. Kok, C.C., McMinn, P.C., Picornavirus RNA-dependent RNA polymerase. Int J Biochem Cell Biol 41 (2009), 498–502.
22. O'Reilly, E.K., Kao, C.C., Analysis of RNA-dependent RNA polymerase structure and function as guided by known polymerase structures and computer predictions of secondary structure. Virology 252 (1998), 287–303.
23. Vignuzzi, M., Stone, J.K., Andino, R., Ribavirin and lethal mutagenesis of poliovirus: molecular mechanisms, resistance and biological implications. Virus Res 107 (2005), 173–181.
24. Kurokawa, M., Ochiai, H., Nagasaka, K., Neki, M., Xu, H., Kadota, S., et al. Antiviral traditional medicines against herpes simplex virus (HSV-1), poliovirus, and measles virus in vitro and their therapeutic efficacies for HSV-1 infection in mice. Antiviral Res 22 (1993), 175–188.
25. Trott, O., Olson, A.J., AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31 (2010), 455–461.
26. Baranovich, T., Wong, S.S., Armstrong, J., Marjuki, H., Webby, R.J., Webster, R.G., et al. T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro. J Virol 87 (2013), 3741–3751.
27. Kortus, M.G., Kempf, B.J., Haworth, K.G., Barton, D.J., Peersen, O.B., A template RNA entry channel in the fingers domain of the poliovirus polymerase. J Mol Biol 417 (2012), 263–278.
28. Sadeghipour, S., Bek, E.J., McMinn, P.C., Ribavirin-resistant mutants of human enterovirus 71 express a high replication fidelity phenotype during growth in cell culture. J Virol 87 (2013), 1759–1769.
29. Ferrer-Orta, C., Sierra, M., Agudo, R., de la Higuera, I., Arias, A., Perez-Luque, R., et al. Structure of foot-and-mouth disease virus mutant polymerases with reduced sensitivity to ribavirin. J Virol 84 (2010), 6188–6199.
30. Arias, A., Arnold, J.J., Sierra, M., Smidansky, E.D., Domingo, E., Cameron, C.E., Determinants of RNA-dependent RNA polymerase (in)fidelity revealed by kinetic analysis of the polymerase encoded by a foot-and-mouth disease virus mutant with reduced sensitivity to ribavirin. J Virol 82 (2008), 12346–12355.
31. Drake, J.W., Rates of spontaneous mutation among RNA viruses. Proc Natl Acad Sci U S A 90 (1993), 4171–4175.
32. Crotty, S., Gohara, D., Gilligan, D.K., Karelsky, S., Cameron, C.E., Andino, R., Manganese-dependent polioviruses caused by mutations within the viral polymerase. J Virol 77 (2003), 5378–5388.
33. Korneeva, V.S., Cameron, C.E., Structure-function relationships of the viral RNA-dependent RNA polymerase: fidelity, replication speed, and initiation mechanism determined by a residue in the ribose-binding pocket. J Biol Chem 282 (2007), 16135–16145.
34. Freistadt, M.S., Eberle, K.E., Conserved aspartic acid 233 and alanine 231 are not required for poliovirus polymerase function in replicons. Virol J, 4, 2007, 28.
35. Diamond, S.E., Kirkegaard, K., Clustered charged-to-alanine mutagenesis of poliovirus RNA-dependent RNA polymerase yields multiple temperature-sensitive mutants defective in RNA synthesis. J Virol 68 (1994), 863–876.
36. Paul, A.V., Mugavero, J., Yin, J., Hobson, S., Schultz, S., van Boom, J.H., et al. Studies on the attenuation phenotype of polio vaccines: poliovirus RNA polymerase derived from Sabin type 1 sequence is temperature sensitive in the uridylylation of VPg. Virology 272 (2000), 72–84.
37. Barton, D.J., Morasco, B.J., Eisner-Smerage, L., Collis, P.S., Diamond, S.E., Hewlett, M.J., et al. Poliovirus RNA polymerase mutation 3D-M394T results in a temperature-sensitive defect in RNA synthesis. Virology 217 (1996), 459–469.
38. Burns, C.C., Richards, O.C., Ehrenfeld, E., Temperature-sensitive polioviruses containing mutations in RNA polymerase. Virology 189 (1992), 568–582.
39. Agut, H., Kean, K.M., Fichot, O., Morasco, J., Flanegan, J.B., Girard, M., A point mutation in the poliovirus polymerase gene determines a complementable temperature-sensitive defect of RNA replication. Virology 168 (1989), 302–311.
40. Jablonski, S.A., Morrow, C.D., Enzymatic activity of poliovirus RNA polymerases with mutations at the tyrosine residue of the conserved YGDD motif: isolation and characterization of polioviruses containing RNA polymerases with FGDD and MGDD sequences. J Virol 67 (1993), 373–381.